- Home
- DTF vs MNOV Comparison
DTF vs MNOV Comparison
Compare DTF & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DTF | MNOV |
|---|---|---|
| Founded | 1991 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.3M | 72.7M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | DTF | MNOV |
|---|---|---|
| Price | $11.47 | $1.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 21.1K | ★ 95.9K |
| Earning Date | 01-01-0001 | 02-18-2026 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | ★ $257,917.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.29 | $1.13 |
| 52 Week High | $11.19 | $2.06 |
Technical Indicators
Market Signals| Indicator | DTF | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 59.96 | 55.60 |
| Support Level | $11.41 | $1.70 |
| Resistance Level | $11.46 | $1.83 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 72.56 | 49.48 |
Price Performance
Historical ComparisonAbout DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing mainly in a diversified portfolio of investment-grade tax-exempt obligations.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.